Darren Shafren
Fondateur chez ImmVirX Pty Ltd.
Profil
Darren Shafren is the founder of ImmVirX Pty Ltd.
He is currently an Associate Professor at The University of Newcastle.
Previously, he served as the Chief Scientific Officer at Viralytics Pty Ltd.
from 2009 to 2019.
Postes actifs de Darren Shafren
| Sociétés | Poste | Début |
|---|---|---|
| The University of Newcastle | Corporate Officer/Principal | - |
ImmVirX Pty Ltd.
 ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Fondateur | - |
Anciens postes connus de Darren Shafren
| Sociétés | Poste | Fin |
|---|---|---|
| VIRALYTICS LTD. | Directeur de la Recherche - Actions | 25/10/2009 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Viralytics Pty Ltd.
 Viralytics Pty Ltd. BiotechnologyHealth Technology Viralytics Pty Ltd. engages in the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to infect and kill cancer cells. Its product, CAVATAK, is a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21. The company was founded in 1984 and is headquartered in Sydney, Australia. | Health Technology |
ImmVirX Pty Ltd.
ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Commercial Services |